GLP-1 drugs associated with significantly lower risk of breast cancer
Women who are overweight or obese and take GLP-1 drugs have about a 30 percent lower risk of developing breast cancer, according to a large U.S. data set. This is the result of a retrospective study by the University of Pennsylvania, which was presented at the ASCO Annual Congress 2026.
The researchers led by Elizabeth McDonald analyzed the health data of more than 110,000 women between the ages of 45 and 80. Those who had been prescribed GLP-1 drugs showed a significantly lower incidence of breast cancer in the evaluation – both in the overall group and in a comparison group adjusted for age, BMI, breast density and other factors.
GLP-1 drugs, which were originally developed to treat type 2 diabetes and are now widely used for weight loss, affect several cancer-related processes, including anti-inflammatory and metabolic regulation. However, the authors emphasize that this is an observational study and no causal effect has been proven.
The results suggest that GLP-1 drugs may have potential cancer-preventing effects beyond weight loss. The researchers are now planning a multicenter clinical trial to test whether these substances can actually reduce the risk of breast cancer in high-risk patients.
The study was published in the journal JCO Oncology Practice .
Read Also:
GLP-1 analogues can trigger unwanted pregnancies – MedLabPortal
Editor: X-Press Journalistenbüro GbR
Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability ected.
Most read
Hantavirus: detection, symptoms, therapy What is hantavirus? Hantaviruses are a group of viruses that occur worldwide and are mainly transmit...- Hantavirus: Facts instead of panic Reports of three deaths in connection with a hantavirus outbreak on the cruise ship "MV Hondius" in...
- NDR research: Many ophthalmologists demand unlawful surcharges for cataract operations According to research by NDR, cataract operations lead to dubious additional claims on a large scale...
